We have been using Heplisav for titer negative employees since October last year – so far 98.2 % positive titers post booster (58 ee)

 

Patricia Higazi  MSN RN COHN

Occupational Health Director

Children’s Hospital of The King’s Daughters

Norfolk, Virginia 23507

Tel: 757 668 7852

Fax: 757 668 8775

 

 

 

From: MCOH-EH [mailto:mcoh-eh-bounces@mylist.net] On Behalf Of Kim.Norton2@hcahealthcare.com
Sent: Wednesday, August 21, 2019 8:37 AM
To: mcoh-eh@mylist.net
Subject: Re: [MCOH-EH] Can Heplisav-B be used for booster dose?
Importance: High

 

External:

 

Hi Tim,

Per the MMWR / January 12, 2018 / Vol. 67 / No. 1 US Department of Health and Human Services/Centers for Disease Control and Prevention.

https://www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6701-H.PDF

 

“Response to Revaccination”

A challenge dose of HepB vaccine may be used to determine the presence of vaccine-induced immunologic memory through generation of an anamnestic response. The term “booster dose” has been used to refer to a dose of HepB vaccine administered after a primary vaccination series to provide” (page 12, bottom right).

 

We utilize this method and have found that the majority will convert to immunity status.

However, we use the Engerix Hep B (01 ml). After booster vaccination, we schedule a Titer retest 6 – 8 weeks later

 

Thank you,

Kim A. Norton, B.S.N., R.N., O.H.N.

Occupational Health Services & Injury Coordinator

It is better to prevent disease rather than to try to find a cure for diseases after they occur.

Mon- Fri 7 a.m. – 3:30 p.m.

407-562-0974 phone

407-302-7323 fax

Kim.Norton2@hcahealthcare.com

Have a human resource (HR) question? – HCA - HRAnswers is available 24/7 by calling 844-472-6797

cid:image001.png@01D4CAB9.BC60D490

Central Florida Regional Hospital                                                                  

https://centralfloridaregional.com/                                                    

This email and any files transmitted with it may contain PRIVILEGED or CONFIDENTIAL information and may be read or used only by the intended recipient. If you are not the intended recipient of the email or any of its attachments, please be advised that you have received this email in error and that any use, dissemination, distribution, forwarding, printing, or copying of this email or any attached files is strictly prohibited. If you have received this email in error, please immediately purge it and all attachments and notify the sender by reply email or contact the sender at the number listed.

          

 

From: MCOH-EH <mcoh-eh-bounces@mylist.net> On Behalf Of Tim Crump
Sent: Tuesday, August 20, 2019 3:08 PM
To: MCOH-EH <mcoh-eh@mylist.net>
Subject: {EXTERNAL} [MCOH-EH] Can Heplisav-B be used for booster dose?

 

We are transitioning over to mostly Heplisav-B for our Hep B vaccinations.  Does anyone have thoughts whether Heplisav-B can be used for a booster dose?  (For example, if a worker had a full documented Hep B series in 2001, but never got a titer till now and it is negative, can we use one Heplisav-B for booster dose, and if the worker has a positive titer after, call them long-term immune?) 

·         Our drug rep says no, that Heplisav is always given as a series of 2 and never as a single dose. 

 

·         To my mind though, anyone with a full Hep B series and a subsequent positive titer has long term immunity, and it shouldn’t matter which vaccine boosts to demonstrate this.

 

What do others think?  The advantage of boosting w/ Heplisav-B would be that if the titer is negative, it would take a lot less time to complete the second series.  Best, Tim

 

 

Tim Crump, MSN, FNP

Tim Crump, MSN, FNP

Family Nurse Practitioner

Multnomah Pavilion 1 SE, Suite 1110

Occupational Health

Healthcare Human Resources

 

Oregon Health & Science University

3181 SW Sam Jackson Park Rd

Mail code: UHN 89

Portland, OR 97239-3098

Department Phone: 503-494-5271

Office Phone: 503-346-1152

Fax: 503-494-4457

Email: crumpt@ohsu.edu

 

Mon-Fri, 7:30-4:00

 

cid:3381310330_334556

 

The information contained in this EMAIL message is confidential and protected by law. The information is intended only for the person or business identified in the document. If you are not the intended recipient, by sharing or copying the information you are breaking the law. If you have received this EMAIL by mistake, please notify the sender of this EMAIL and do not return, copy or keep the information in the EMAIL.